Catalyst
Slingshot members are tracking this event:
FDA Grants Priority Review for Opdivo (nivolumab) in Previously Treated dMMR or MSI-H Metastatic Colorectal Cancer - PDUFA set for Aug. 2, 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| BMY |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 01, 2017
Occurred Source:
https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-receives-fda-approval-opdivo-nivolumab-ms
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Opdivo, Nivolumab, Pdufa, Dmmr, Msi-h Metastatic Colorectal Cance, Colorectal Cancer
